Programme - Saturday, October 9, 2021

08.00 – 09.20   Session 7: Cell Therapy in Solid Tumors

Chair: Michael Hudecek and Simon Heidegger

 

08.00 – 08.20   07.01 - Immunogeneic chemotherapy for breaking resistance to CAR T cells in solid tumors             

Stanley Riddell, Seattle, WA, USA

 

08.20 – 08.40   07.02 - Redirecting CAR T cells to cancer tissue using chemokine receptors

Sebastian Kobold, Munich, Germany

 

08.40 – 09.00   07.03 - Anti CD20 directed CAR T in Malignant Melanoma

Michael von Bergwelt, Munich, Germany

 

09.00 – 09.20   07.04 - ADP-A2M4CD8 in HLA-A2+ Subjects with MAGE-A4 Positive solid tumors

David S. Hong, Houston, TX, USA

 

09.20 – 09.50   We invite you to visit the virtual stands and on-demand symposia of our sponsors, as well as to view the 

e-poster presentations of your colleagues.

​

09.50 – 10.20   Coffee Break

 

10.20 – 11.40   Session 8: Cell Therapy in Haematologic Diseases

Chair: Hinrich Abken and Anita Kremer 

 

10.20 – 10.40   08.01 - Visualizing CAR T cells at work

Philippe Bousso, Paris, France

 

10.40 – 11.00   08.02 - Dissecting CAR T cell resistance in lymphomas

Marco Ruella, Philadelphia, PA, USA

 

11.00 – 11.20   08.03 - TCR transgenetic T cells

Dirk Busch, Munich, Germany 

 

11.20 – 11.40   08.04 - CAR armed NK cells for cancer treatment

May Daher, Houston, TX, USA

 

11.40 – 12.15   Session 9: Lifetime Achievement Award

Chair: Christoph Zielinski and Michael von Bergwelt

09.01 - Translating the success of the mRNA vaccine to cancer

Uğur Şahin and Özlem Türeci, BioNtech SE, Mainz, Germany

 

12.15 – 13.00   Lunch Break

 

13.00 – 13.30   We invite you to visit the virtual stands and on-demand symposia of our sponsors, as well as to view the 

e-poster presentations of your colleagues.

​

13.30 – 14.50   Session 10: Young Researcher Session

Chair: Sophia Stock and Sebastian Kobold

 

13.30 – 13.50   10.01 - Effective solid tumor therapy through enhanced recruitment and immune suppression shielded T cells

Bruno Cadilha, Munich, Germany
 

13.50 – 14.10   10.02 - Genomic HLA homozygosity is frequent in esophageal adenocarcinoma and related to low immunogenicity

Maria Garcia-Marquez, Cologne, Germany

​

14.10 – 14.30   10.03 - Interleukin-22 regulates anti-tumor immunity in mouse models of lung and breast carcinoma

Daria Briukhovetska, Munich, Germany

​

14.30 – 14.50   10.04 - A library of novel Cancer Testis specific T-cell receptors for T-cell receptor gene therapy

Marije de Rooij, Leiden, Netherlands

14.50 – 15.20   Coffee Break

 

15.20 – 16.40   Session 11: Combination Therapy

Chair: Michael Bergmann and Wenru Song

 

15.20 – 15.40   11.01 - Cancer-specific nanoparticle-based Photodynamic/photothermal therapy synergizes immunotherapy

in bladder cancer

Chong-Xian Pan, Boston, MA, USA

 

15.40 – 16.00   11.02 - Systemic effects of local administration of anti-CTLA4 in early-stage melanoma

Tanja de Gruijl, Amsterdam, The Netherlands

 

16.00 – 16.20   11.03 - Novel molecular and immune mechanisms to enhance radiation + checkpoint immunotherapy

Jason Luke, Pittsburgh, PA, USA

 

16.20 – 16.40   11.04 - CD40 Combinations

Gregory L. Beatty, Philadelphia, PA, USA

​

16.40 – 17.00   Session 12: Best Poster Awards & Closing Remarks

Chair: Volkmar Nüssler and Sebastian Kobold

​

​